Related Experiment Video
Updated: Feb 11, 2026

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
Divergent effects of strontium and calcium-sensing receptor positive allosteric modulators (calcimimetics) on human
Natalie A Diepenhorst1, Katie Leach1, Andrew N Keller1
1Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Background And Purpose:
Strontium ranelate, a drug approved and until recently used for the treatment of osteoporosis, mediates its effects on bone at least in part via the calcium-sensing (CaS) receptor. However, it is not known whether bone-targeted CaS receptor positive allosteric modulators (PAMs; calcimimetics) represent an alternative (or adjunctive) therapy to strontium (Sr2+ o ).
Experimental Approach:
We assessed three structurally distinct calcimimetics [cinacalcet, AC-265347 and a benzothiazole tri-substituted urea (BTU-compound 13)], alone and in combination with extracellular calcium (Ca2+ o ) or Sr2+ o , in G protein-dependent signalling assays and trafficking experiments in HEK293 cells and their effects on cell differentiation, tartrate-resistant acid phosphatase (TRAP) activity and hydroxyapatite resorption assays in human blood-derived osteoclasts.
Key Results:
Sr2+ o activated CaS receptor-dependent signalling in HEK293 cells in a similar manner to Ca2+ o , and inhibited the maturation, TRAP expression and hydroxyapatite resorption capacity of human osteoclasts. Calcimimetics potentiated Ca2+ o - and Sr2+ o -mediated CaS receptor signalling in HEK293 cells with distinct biased profiles, and only cinacalcet chaperoned an endoplasmic reticulum-retained CaS mutant receptor to the cell surface in HEK293 cells, indicative of a conformational state different from that engendered by AC-265347 and BTU-compound 13. Intriguingly, only cinacalcet modulated human osteoclast function, reducing TRAP activity and profoundly inhibiting resorption.
Conclusion And Implications:
Although AC-265347 and BTU-compound 13 potentiated Ca2+ o - and Sr2+ o -induced CaS receptor activation, they neither replicated nor potentiated the ability of Sr2+ o to inhibit human osteoclast function. In contrast, the FDA-approved calcimimetic, cinacalcet, inhibited osteoclast TRAP activity and hydroxyapatite resorption, which may contribute to its clinical effects on bone mineral density LINKED ARTICLES: This article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.21/issuetoc.
Insights
The calcimimetic cinacalcet, unlike other tested compounds, inhibits osteoclast function, suggesting potential for osteoporosis treatment. Strontium (Sr2+o) also impacts bone cells via the calcium-sensing receptor.
Area of Science:
- Pharmacology
- Bone Biology
- Molecular Signaling
Background:
- Strontium ranelate, an osteoporosis drug, acts partly via the calcium-sensing (CaS) receptor.
- The potential of CaS receptor positive allosteric modulators (calcimimetics) as osteoporosis therapies is unexplored.
Purpose of the Study:
- To investigate if calcimimetics can serve as alternative or adjunctive therapies to strontium for osteoporosis.
- To compare the effects of different calcimimetics on CaS receptor signaling and osteoclast function.
Main Methods:
- Assessed three calcimimetics (cinacalcet, AC-265347, BTU-compound 13) in G protein signaling and trafficking assays in HEK293 cells.
- Evaluated calcimimetics' effects on human osteoclast differentiation, TRAP activity, and resorption in vitro.
- Tested calcimimetics alone and with extracellular calcium (Ca2+o) or strontium (Sr2+o).
Main Results:
- Sr2+o activated CaS receptor signaling similarly to Ca2+o and inhibited osteoclast maturation and resorption.
- Calcimimetics potentiated Ca2+o- and Sr2+o-mediated CaS receptor signaling with biased profiles.
- Only cinacalcet normalized CaS receptor trafficking and significantly inhibited osteoclast TRAP activity and resorption.
Conclusions:
- AC-265347 and BTU-compound 13 did not replicate Sr2+o's inhibitory effects on osteoclasts.
- Cinacalcet's inhibition of osteoclast function suggests a potential role in treating bone diseases like osteoporosis.
- Calcimimetics exhibit distinct effects on CaS receptor signaling and osteoclast biology.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
12:02High-throughput Analysis of Mammalian Olfactory Receptors: Measurement of Receptor Activation via Luciferase Activity
Published on: June 2, 2014
Related Concept Videos
Cooperative Allosteric Transitions
Cooperative Allosteric Transitions
Internal Receptors
Divergence and Curl
Divergence and Stokes' Theorems
Gene Duplication and Divergence
The duplicated copies of the gene are called Paralogs. Paralogs with similar sequences and functions form a gene family. Across several species, a large number of gene families are...